
Press Release|Articles|January 7, 2025
Camber Pharmaceuticals Announces Addition of Bortezomib for Injection
Listen
0:00 / 0:00
Key Takeaways
- Bortezomib for Injection is a proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma in adults.
- The medication is available in a 3.5 mg strength, packaged in a single-dose vial.
Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.
Bortezomib for Injection is a proteasome inhibitor indicated for:
- treatment of adult patients with multiple myeloma
- treatment of adult patients with mantle cell lymphoma
Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.
To find out more information on Bortezomib for Injection please visit:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5

























